Article
Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway
1 Dec 2020
Abstract excerpt
Colorectal cancer (CRC) accounts for about 10% of all annually diagnosed cancers and cancer-related deaths worldwide. STAT3 plays a vital role in the occurrence and development of tumours. Gracillin has shown a significant antitumour activity in tumours, but its mechanism remains unknown. The human CRC cell lines HCT116, RKO, and SW480 and immunodeficient mice were used as models to study the effects of gracillin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
